IC
TERN

Ikarian Capital’s Terns Pharmaceuticals TERN Stock Holding History

Ikarian Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.8M Sell
1,456,378
-140,000
-9% -$5.75M 6.23% 2
2025
Q4 		$64.5M Buy
1,596,378
+1,432,176
+872% +$33.1M 5.04% 4
2025
Q3 		$1.23M Buy
164,202
+105,711
+181% +$675K 0.12% 116
2025
Q2 		$218K Sell
58,491
-250,000
-81% -$781K 0.04% 111
2025
Q1 		$851K Hold
308,491
– – 0.1% 100
2024
Q4 		$1.71M Sell
308,491
-6
-0% -$41 0.23% 86
2024
Q3 		$2.57M Sell
308,497
-150,000
-33% -$1.23M 0.36% 68
2024
Q2 		$3.12M Buy
458,497
+370,000
+418% +$2.24M 0.54% 45
2024
Q1 		$581K Sell
88,497
-76,983
-47% -$503K 0.06% 116
2023
Q4 		$1.07M Hold
165,480
– – 0.1% 98
2023
Q3 		$832K Sell
165,480
-150,000
-48% -$952K 0.1% 101
2023
Q2 		$2.76M Sell
315,480
-405,861
-56% -$4.73M 0.44% 54
2023
Q1 		$8.54M Sell
721,341
-15,978
-2% -$153K 1.94% 14
2022
Q4 		$7.51M Sell
737,319
-166,800
-18% -$1.11M 1.81% 18
2022
Q3 		$5.33M Buy
904,119
+204,119
+29% +$758K 1.06% 33
2022
Q2 		$1.74M Buy
+700,000
New +$1.4M 0.32% 64

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Ikarian Capital's TERN Position: Q1 2026 in Review

Ikarian Capital reduced its Terns Pharmaceuticals (TERN) stake by 8.8% in Q1 2026, selling an estimated $5.75M and leaving 1,456,378 shares worth $76.8M. The position accounts for 6.23% of the portfolio, ranked #2.

Ikarian Capital first reported a position in TERN in Q2 2022 and has held it in 16 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Ikarian Capital held 1,456,378 shares of Terns Pharmaceuticals worth $76.8M as of Q1 2026.
  • Ikarian Capital sold 140,000 Terns Pharmaceuticals shares in Q1 2026, an estimated $5.75M.
  • Terns Pharmaceuticals made up 6.23% of Ikarian Capital's portfolio in Q1 2026, its #2 holding.
  • Ikarian Capital first reported a position in Terns Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.